562,391 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Acquired by First Turn Management LLC

First Turn Management LLC acquired a new position in Bicara Therapeutics Inc. (NASDAQ:BCAX) in the third quarter, Holdings Channel reports. The fund acquired 562,391 shares of the company’s stock, valued at approximately $14,324,000. Bicara Therapeutics makes up approximately 2.3% of First Turn Management LLC’s investment portfolio, making the stock its 24th biggest position.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on BCAX. Rodman & Renshaw began coverage on shares of Bicara Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating and a $48.00 price objective for the company. TD Cowen assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They issued a “buy” rating for the company. Stifel Nicolaus assumed coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They issued a “buy” rating and a $47.00 price target on the stock. RODMAN&RENSHAW raised shares of Bicara Therapeutics to a “strong-buy” rating in a report on Tuesday, November 5th. Finally, Morgan Stanley assumed coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They issued an “overweight” rating and a $35.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $43.33.

Bicara Therapeutics Stock Performance

NASDAQ BCAX opened at $19.20 on Tuesday. Bicara Therapeutics Inc. has a 12-month low of $18.33 and a 12-month high of $28.09. The business has a fifty day moving average price of $23.33.

Bicara Therapeutics (NASDAQ:BCAX) last released its earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($1.14). Sell-side analysts anticipate that Bicara Therapeutics Inc. will post -2.89 EPS for the current year.

Insider Activity at Bicara Therapeutics

In other news, Director Ra Capital Management, L.P. bought 1,833,000 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The shares were purchased at an average cost of $18.00 per share, with a total value of $32,994,000.00. Following the transaction, the director now directly owns 4,303,418 shares in the company, valued at approximately $77,461,524. The trade was a 74.20 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder James E. Flynn bought 70,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $1,260,000.00. Following the completion of the transaction, the insider now owns 897,587 shares in the company, valued at $16,156,566. This trade represents a 8.46 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Bicara Therapeutics Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.